Bay Area may be at risk from synthetic biology research labs
By Emily Smith Beitiks,
San Jose Mercury News
| 03. 27. 2012
Lawrence Berkeley National Laboratory recently announced a proposal to build a facility in Richmond at which synthetic biology research will be a major focus. This news should give us pause to consider exactly what risks this little-known field poses for the environment and human health.
Last year, molecular biologist Becky McClain was awarded $1.37 million in a whistle-blower suit against the pharmaceutical giant Pfizer after she was fired for raising safety concerns about the lab where she worked. McClain was infected with a genetically engineered virus being researched in her lab. She continues to experience intermittent paralysis and spinal pain, symptoms consistent with the effects of the pathogen.
McClain's story offers an important lesson for assessing a new kind of bioengineering: the rapidly growing field of synthetic biology, which has already been called genetic engineering on steroids.
Synthetic biologists build artificial organisms using the building blocks of life. While techniques vary, the intent is the same: to create life from scratch. Proponents promise extraordinary benefits, from curing diseases to replacing fossil fuels. But the unknowns are as serious as they...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...